Dong-A ST Co., Ltd. (KRX:170900)

South Korea flag South Korea · Delayed Price · Currency is KRW
48,100
-50 (-0.10%)
At close: Jun 5, 2025, 3:30 PM KST
-22.12%
Market Cap 440.75B
Revenue (ttm) 724.59B
Net Income (ttm) -781.19M
Shares Out 9.16M
EPS (ttm) -87.58
PE Ratio n/a
Forward PE 21.75
Dividend 686.27 (1.43%)
Ex-Dividend Date Mar 13, 2025
Volume 16,337
Average Volume 17,454
Open 48,100
Previous Close 48,150
Day's Range 47,850 - 48,500
52-Week Range 40,900 - 79,118
Beta 0.50
RSI 56.03
Earnings Date Jul 28, 2025

About Dong-A ST

Dong-A ST Co., Ltd. develops, manufactures, and markets pharmaceutical products in South Korea and internationally. It offers various ethical drugs, including Closerin Cap for active pulmonary and extra-pulmonary tuberculosis; Dulastin PFS and Leucostim injection/PFS to treat neutropenia in patients receiving myelosuppressive chemotherapy; Eporon inj./PFS for anemia associated with chronic renal failure; Gemcit inj. to treat non-small cell lung, pancreatic, breast, bladder, and ovarian cancers; Gonadopin inj./PFS for infertility and anovulation... [Read more]

Sector Healthcare
Founded 1932
Employees 1,687
Stock Exchange Korea Stock Exchange
Ticker Symbol 170900
Full Company Profile

Financial Performance

Financial Statements

News

Dong-A ST Secures European Approval for Stelara Biosimilar IMULDOSA

– Global Market Expansion Accelerates with Back-to-Back FDA and EC Authorizations SEOUL, South Korea — Dong-A ST (CEO: Jeong Jae-hoon, KRX: 170900) proudly announces that its Stelara biosimilar, IMULD...

6 months ago - Financial Post

US FDA Approves Dong-A ST’s IMULDOSA™ (ustekinumab-srlf), a Biosimilar to STELARA®

Dong-A ST’s biologics license application (BLA) for Imuldosa, submitted in October 2023, is approved by the U.S. Food and Drug Administration SEOUL, South Korea — Dong-A ST (President/CEO Jae-Hun Jung...

8 months ago - Financial Post

US FDA Approves Dong-A ST's IMULDOSA™ (ustekinumab-srlf), a Biosimilar to STELARA®

Dong-A ST's biologics license application (BLA) for Imuldosa, submitted in October 2023, is approved by the U.S. Food and Drug Administration Dong-A ST (President/CEO Jae-Hun Jung, KRX: 170900) announ...

8 months ago - Benzinga